Topic: initial public offering
Astellas buys gene therapy player Audentes for $3 billion. Keytruda and Opdivo fail to win coverage in China. Hanmi inks I-O deal with Rapt.
Takeda's rare disease sales dropped sharply. Astellas teamed with Pandion on Type 1 diabetes. Shanghai's I-Mab filed for a $100 million Nasdaq IPO.
Keytruda-Lenvima combo wins simultaneous OKs. Eisai and Biogen ditch second BACE drug. Sanofi is leaving Bangladesh. Henlius raises $410 million.
Big Pharma's older drugs face pricing pressure in China; Pfizer moves Upjohn HQ to Shanghai; Hansoh Pharma eyes $1 billion Hong Kong IPO.
Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.
Eisai's stock plummets at AD failure; Keytruda has much upside in China, analysts say; Korea Exchange is dragged into Samsung accounting probe.
Despite clear signs of health, the biopharma industry is under pressure to increase volume sales with M&A, Vantage analysts say.
Bernstein analysts has recently figured selling animal health is "a real possibility" for Bayer and suggested management to consider it for pharma's sake.
Another cell manufacturing facility will be built in the U.S., this by a transatlantic biotech in which GlaxoSmithKline owns a sizable share.
Little more than a week after investors hailed Lilly’s plan to spin off Elanco, it filed IPO plans showing the animal health unit has some growing pains.